Wall Street Zen Upgrades Kamada (NASDAQ:KMDA) to Strong-Buy

Kamada (NASDAQ:KMDA) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “strong-buy” rating in a report released on Saturday.

KMDA has been the subject of several other research reports. Weiss Ratings cut shares of Kamada from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 25th. William Blair set a $15.00 price target on Kamada in a research note on Tuesday, July 21st. Finally, Benchmark reaffirmed a “buy” rating on shares of Kamada in a report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Kamada currently has a consensus rating of “Buy” and an average price target of $13.00.

Kamada Price Performance

NASDAQ:KMDA opened at $7.58 on Friday. Kamada has a one year low of $6.50 and a one year high of $9.35. The company has a fifty day moving average price of $7.22 and a 200 day moving average price of $7.96. The stock has a market cap of $435.93 million, a P/E ratio of 19.95, a PEG ratio of 0.67 and a beta of 0.86.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.05. Kamada had a net margin of 11.60% and a return on equity of 8.37%. The company had revenue of $54.92 million for the quarter, compared to analyst estimates of $50.84 million. As a group, equities research analysts anticipate that Kamada will post 0.45 EPS for the current year.

Hedge Funds Weigh In On Kamada

A number of hedge funds have recently made changes to their positions in KMDA. Man Group plc lifted its holdings in shares of Kamada by 19.9% during the 4th quarter. Man Group plc now owns 34,294 shares of the biotechnology company’s stock worth $242,000 after acquiring an additional 5,684 shares during the period. SIH Partners LLLP acquired a new stake in shares of Kamada during the 4th quarter valued at about $134,000. Aristides Capital LLC increased its stake in Kamada by 4.5% in the fourth quarter. Aristides Capital LLC now owns 33,015 shares of the biotechnology company’s stock valued at $233,000 after acquiring an additional 1,430 shares during the period. JPMorgan Chase & Co. increased its stake in Kamada by 43.6% in the third quarter. JPMorgan Chase & Co. now owns 40,984 shares of the biotechnology company’s stock valued at $284,000 after acquiring an additional 12,442 shares during the period. Finally, Jump Financial LLC acquired a new position in Kamada in the second quarter worth about $219,000. Institutional investors and hedge funds own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.